Filtered By:
Drug: Celebrex
Education: Study
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you…
Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China.
I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1
We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004.
Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news
Synthesis and biological evaluation of resveratrol amide derivatives as selective COX-2 inhibitors
Chem Biol Interact. 2023 May 11:110522. doi: 10.1016/j.cbi.2023.110522. Online ahead of print.ABSTRACTSelective COX-2 inhibitors have been considered to be reliable alternatives to tNSAIDs, but most of them were withdrawn from the market due to their risk of heart attack and stroke. Therefore, it is urgent to develop a new type of selective COX-2 inhibitor with high efficiency and low toxicity. Inspired by the cardiovascular protection, and anti-inflammatory activity of resveratrol, we synthesized 38 resveratrol amide derivatives and evaluated their COX-1/COX-2 inhibitory activities. Compounds 8a, 6a, 8c and 13c showed imp...
Source: Chemico-Biological Interactions - May 13, 2023 Category: Molecular Biology Authors: Min Xin Haoyu Wu Yuan Du Sheng Liu Feng Zhao Xiaofeng Mou Source Type: research
Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study
ConclusionThis population-based retrospective cohort study has shown that Celecoxib and Etoricoxib reduce the risk of ischemic stroke in patients with RA in a dose- and time-dependent manner.
Source: Frontiers in Neurology - October 20, 2022 Category: Neurology Source Type: research
Comparative Risks of Nonsteroidal Antiinflammatory Drugs on Cardiovascular Diseases: A Population-Based Cohort Study
This article is protected by copyright. All rights reserved.PMID:36063443 | DOI:10.1002/jcph.2142
Source: The Journal of Clinical Pharmacology - September 5, 2022 Category: Drugs & Pharmacology Authors: Eric Yuk Fai Wan Esther Yee Tak Yu Linda Chan Anna Hoi Ying Mok Yuan Wang Esther Wai Yin Chan Ian Chi Kei Wong Cindy Lo Kuen Lam Source Type: research
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
CONCLUSIONS: There is no evidence to support the use of low-dose aspirin or other NSAIDs of any class (celecoxib, rofecoxib or naproxen) for the prevention of dementia, but there was evidence of harm. Although there were limitations in the available evidence, it seems unlikely that there is any need for further trials of low-dose aspirin for dementia prevention. If future studies of NSAIDs for dementia prevention are planned, they will need to be cognisant of the safety concerns arising from the existing studies.
PMID: 32352165 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - April 29, 2020 Category: General Medicine Authors: Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, Murphy K, Devane D Tags: Cochrane Database Syst Rev Source Type: research
Differences in cardiovascular safety with non ‐steroidal anti‐inflammatory drug therapy ‐ a nationwide study in patients with osteoarthritis
This article is protected by copyright. All rights reserved.
Source: Basic and Clinical Pharmacology and Toxicology - November 28, 2018 Category: Drugs & Pharmacology Authors: Carlo Alberto Barcella,
Morten Lamberts,
Patricia McGettigan,
Emil Loldrup Fosb øl,
Jesper Lindhardsen,
Christian Torp‐Pedersen,
Gunnar Hilmar Gislason,
Anne‐Marie Schjerning Olsen Tags: Original Article Source Type: research
Comparative cardiovascular safety of nonsteroidal anti ‐inflammatory drugs in patients with hypertension: a population‐based cohort study
ConclusionsOur results provide important information about the comparative cardiovascular safety of NSAIDs in patients with hypertension.
Source: British Journal of Clinical Pharmacology - March 13, 2018 Category: Drugs & Pharmacology Authors: Yaa ‐Hui Dong, Chia‐Hsuin Chang, Li‐Chiu Wu, Jing‐Shiang Hwang, Sengwee Toh Tags: DRUG SAFETY Source Type: research
Comparative cardiovascular safety of non ‐steroidal anti‐inflammatory drugs in patients with hypertension: a population‐based cohort study
ConclusionsOur results provide important information about the comparative cardiovascular safety of NSAIDs in patients with hypertension.
Source: British Journal of Clinical Pharmacology - February 22, 2018 Category: Drugs & Pharmacology Authors: Yaa ‐Hui Dong, Chia‐Hsuin Chang, Li‐Chiu Wu, Jing‐Shiang Hwang, Sengwee Toh Tags: DRUG SAFETY Source Type: research
Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year.
In 2015, the FDA asked drug makers to strengthen their warning labels.
Since then, most have listed their dangerous side effects on the bottle.
But one manufacturer thought they didn’t have to warn people about their dangerous drug.
They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1
The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche.
...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news
Celecoxib for rheumatoid arthritis.
CONCLUSIONS: Celecoxib may improve clinical symptoms, alleviate pain and contribute to little or no difference in physical function compared with placebo. Celecoxib was associated with fewer numbers of participant withdrawals. Results for incidence of gastroduodenal ulcers (≥ 3 mm) and short-term serious adverse events were uncertain; however, there were few reported events for either.Celecoxib may slightly improve clinical symptoms compared with tNSAIDs. Results for reduced pain and improved physical function were uncertain. Particpants taking celecoxib had lower incidence of gastroduodenal ulcers (≥ 3 mm) and there w...
Source: Cochrane Database of Systematic Reviews - June 9, 2017 Category: General Medicine Authors: Fidahic M, Jelicic Kadic A, Radic M, Puljak L Tags: Cochrane Database Syst Rev Source Type: research
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Authors: Tacconelli S, Bruno A, Grande R, Ballerini P, Patrignani P
Abstract
INTRODUCTION: The pharmacological management of pain includes the use of nonsteroidal anti-inflammatory drugs(NSAIDs). They comprise traditional(t) NSAIDs and selective cyclooxygenase(COX)-2 inhibitors (named coxibs). The analgesic and anti-inflammatory effects of NSAIDs are dependent on the extent and duration of COX-2 inhibition in the spinal cord and inflammatory sites. However, the simultaneous inhibition of COX-2 in the vasculature translates into a prothrombotic phenotype and promotes hypertension and heart failure. Areas covered. Th...
Source: Expert Opinion on Drug Safety - June 2, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Non ‐steroidal anti‐inflammatory drug‐induced cardiovascular adverse events: a meta‐analysis
Summary
What is known and objectiveAlthough non‐steroidal anti‐inflammatory drugs (NSAIDs) have been studied in randomized, controlled trials and meta‐analyses in an effort to determine their cardiovascular (CV) risks, no consensus has been reached. These studies continue to raise questions, including whether cyclooxygenase‐2 (COX‐2) selectivity plays a role in conferring CV risk. We performed a meta‐analysis of current literature to determine whether COX‐2 selectivity leads to an increased CV risk.
MethodsWe utilized randomized, controlled trials and prospective cohort studies. We selected eight NSAIDs based...
Source: Journal of Clinical Pharmacy and Therapeutics - November 30, 2016 Category: Drugs & Pharmacology Authors: B. R. Gunter, K. A. Butler, R. L. Wallace, S. M. Smith, S. Harirforoosh Tags: Review Article Source Type: research
Celebrex study shows less risk to heart health than expected
Researchers spend a decade studying Celebrex, an arthritis drug, to see if it causes heart problems. A similar drug was removed from the market in 2004, as it increased the risk of heart attack and stroke. Dr. Jon LaPook reports.
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news
